Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with "negative" or preliminary results and basic science studies with provocative findings.
实验血液学和肿瘤学是一个开放获取，同行评审的在线期刊，涵盖血液学和肿瘤学的所有方面，重点是临床前，基础，面向患者和转化研究。该杂志是共享这些领域实验室发现的国际平台，并有意发表具有 “阴性” 或初步结果的临床试验以及具有挑衅性发现的基础科学研究。
Advances and perspectives of PARP inhibitors
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0154-9
Immunotherapy in extensive small cell lung cancer
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0129-x
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0143-z
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0133-1
Mantle cell lymphoma and its management: where are we now?
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0126-0
Recent advances on blinatumomab for acute lymphoblastic leukemia
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0152-y
Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0127-z
Targeted and novel therapy in advanced gastric cancer
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0149-6
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0150-0
NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0135-z
Gut microbiome and CAR-T therapy
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0155-8
Novel GTF2I–PDGFRB and IKZF1–TYW1 fusions in pediatric leukemia with normal karyotype
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0136-y
An expanded biomarker panel for the detection of prostate cancer from urine DNA
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0137-x
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0134-0
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0141-1
Frontline therapies for untreated chronic lymphoid leukemia
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0139-8
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0138-9
Role of some members of chemokine/cytokine network in the pathogenesis of thalassemia and sickle cell hemoglobinopathies: a mini review
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0145-x
Immune pressures drive the promoter hypermethylation of neoantigen genes
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0156-7
Development of molecular and pharmacological switches for chimeric antigen receptor T cells
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0151-z
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-018-0125-6
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0132-2
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0153-x
A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0144-y
Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0140-2
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0128-y
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0148-7
LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0147-8
Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0130-4
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0131-3
Cabozantinib and apixaban: an hitherto unreported interaction
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0146-9
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
来源期刊：Experimental Hematology & OncologyDOI：10.1186/s40164-019-0142-0
